HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Nerve Sheath Neoplasms (Nerve Sheath Neoplasm)

Subscribe to New Research on Nerve Sheath Neoplasms

Neoplasms which arise from nerve sheaths formed by SCHWANN CELLS in the PERIPHERAL NERVOUS SYSTEM or by OLIGODENDROCYTES in the CENTRAL NERVOUS SYSTEM. Malignant peripheral nerve sheath tumors, NEUROFIBROMA, and NEURILEMMOMA are relatively common tumors in this category.

Also Known As:

Nerve Sheath Neoplasm; MPNST; Malignant Peripheral Nerve Sheath Tumors; Neoplasms, Nerve Sheath; Nerve Sheath Tumors; Nerve Sheath Tumors, Peripheral; Peripheral Nerve Sheath Tumors, Malignant; Tumors of the Nerve Sheath; MPNSTs; Neoplasm, Nerve Sheath; Perineuriomas; Perineurioma; Peripheral Nerve Sheath Tumors

Networked: 380 relevant articles (14 outcomes, 48 trials/studies) for this Disease, Comments

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Neoplasms (Cancer)
2.	Sarcoma (Soft Tissue Sarcoma)
3.	Neoplasm Metastasis (Metastasis)
4.	Neuroblastoma
5.	Necrosis

Experts

1.	Carroll, Steven L: 9 articles (05/2012 - 08/2003)
2.	Guha, Abhijit: 7 articles (04/2012 - 09/2002)
3.	Gutmann, David H: 7 articles (04/2011 - 09/2002)
4.	von Deimling, Andreas: 7 articles (01/2010 - 02/2004)
5.	Holtkamp, Nikola: 7 articles (01/2010 - 02/2004)
6.	Friedrich, Reinhard E: 5 articles (01/2013 - 02/2004)
7.	Ratner, Nancy: 5 articles (10/2012 - 05/2008)
8.	Upadhyaya, Meena: 5 articles (04/2012 - 02/2004)
9.	Mautner, Victor-F: 5 articles (12/2008 - 02/2004)
10.	Lev, Dina: 4 articles (08/2012 - 01/2009)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Nerve Sheath Neoplasms:

1.	Sirolimus (Rapamycin)FDA Link 05/01/2008 - "Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors." 01/15/2010 - "This study demonstrates the therapeutic potential and limitations of rapamycin in NF1-associated, and likely sporadic, MPNSTs." 01/01/2012 - "To determine the significance of Pten status for treatment with the mTOR inhibitor rapamycin we treated 5 MPNST cell lines with rapamycin. " 05/01/2009 - "MPNST cells were sensitive to rapamycin; however, rapamycin enhanced pAKT and peIF4E expression. " 01/01/2010 - "Finally, increased knowledge of molecular and cellular mechanisms involved with NF1 tumorigenesis has led to multiple preclinical and clinical studies of targeted therapy, including the mTOR inhibitor rapamycin, which is demonstrating promising preclinical results for treatment of MPNSTs and gliomas." Order ALL the reference details at left...
2.	S100 Proteins (S 100 Protein)IBA 07/01/2009 - "This study indicates that the TMA technique can be used in the IHC study of MPNSTs, even with the use of heterogeneous markers such as S-100 protein." 05/01/2011 - "The lack of S-100 protein expression made Schwann cells an unlikely cell of origin, as opposed to peripheral nerve sheath tumors, which typically express S-100 protein, at least in some neoplastic cells. " 03/01/2006 - "For example, S-100 protein is widely used in the diagnosis of MPNST. " 10/01/2004 - "The schwannomatous component was immunohistochemically S-100 protein positive and CD34 and EMA negative, and the perineuriomatous component had the appearance of retiform perineurioma. " 11/01/2003 - "These findings suggest that careful clinical and histological evaluation, along with S-100 protein immunostaining, are essential for the accurate diagnosis of low grade MPNST." Order ALL the reference details at left...
3.	Messenger RNA (mRNA)IBA 05/01/2004 - "This study represents a comprehensive gene-expression analysis of an MPNST-derived cell line and the first comprehensive global mRNA profile of nhSCs in culture. " 10/01/2012 - "MPNSTs (n=28) showed variable levels of Sox10 and S100 mRNA expression, and these expression levels were highly correlated (Pearson correlation coefficient r=0.79). " 05/01/2012 - "Human MPNST cell lines exhibited survivin mRNA and protein overexpression; expression in both nuclear and cytoplasmic compartments was noted. " 01/21/2010 - "EYA4 mRNA was elevated more than 100-fold as estimated by quantitative real-time PCR in most MPNST cell lines. " 10/01/2001 - "Transcriptional mRNA of BMP-2, 3, 4 and 5 in trigeminal nerve, benign and malignant peripheral nerve sheath tumors." Order ALL the reference details at left...
4.	Doxorubicin (Adriamycin)FDA LinkGeneric 06/15/2009 - "These findings indicate that constitutive hyaluronan-CD44 interactions contribute to drug transporter localization and function at the plasma membrane, and that attenuating hyaluronan-CD44 interactions sensitizes MPNSTs to doxorubicin in vitro and in vivo. " 06/15/2009 - "MPNSTs are multidrug resistant, and thus long-term patient survival rates are poor after standard doxorubicin or multiagent chemotherapies. " 08/01/2012 - "We further demonstrated that either depletion of Bcl-xL expression by RNAi or inactivation of Bcl-xL by ABT-737, a mimetic of the BH3-only protein BAD, was very effective in sensitizing the MPNST cells to apoptotic cell death by combined treatment with the tested anticancer drug doxorubicin. " 08/01/2012 - "These results suggest that pharmacological inhibition of Bcl-xL by ABT-737 in combination with doxorubicin can be a potential therapeutic strategy for the treatment of NF1-associated MPNSTs." 08/01/2012 - " Notably, a low concentration of ABT-737 and doxorubicin could effectively induce synergistic cytotoxicity in the MPNST cells. " Order ALL the reference details at left...
5.	Tamoxifen FDA LinkGeneric 01/01/2011 - "Tamoxifen was also effective in vivo, demonstrating potent antitumor activity in mice orthotopically xenografted with human MPNST cells. " 01/01/2011 - "The in vivo effectiveness of tamoxifen provides a rationale for clinical trials in cases of MPNSTs." 01/01/2011 - "Further, ablation of ERβ and GPER had no effect on MPNST proliferation, survival, or tamoxifen sensitivity, indicating that tamoxifen acts via an ER-independent mechanism. " 01/01/2011 - "To test this hypothesis, we examined tamoxifen effects on MPNST cell proliferation and survival, MPNST xenograft growth, and the mechanism by which tamoxifen impeded these processes. " 01/01/2011 - "Guided by clinical observations suggesting that some NF1-associated nerve sheath tumors are hormonally responsive, we hypothesized that the selective estrogen receptor (ER) modulator tamoxifen would inhibit MPNST tumorigenesis in vitro and in vivo. " Order ALL the reference details at left...
6.	Platelet-Derived Growth Factor beta Receptor (Receptor, Platelet Derived Growth Factor beta)IBA 12/01/2009 - "In conclusion, PDGFRA, PDGFRB, and EGFR seem to be promising molecular targets for tailored treatments in MPNST. " 08/01/2007 - "No mutations were present in exons 12 and 18 of PDGFR-beta in both MPNST cell lines and 10 human MPNST tissues examined. " 02/01/2005 - "As examined by Western blotting, PDGF-beta receptor expression levels were similar in nhSC and NF1 MPNST cell lines. " 02/01/2005 - "We characterized platelet-derived growth factor-beta (PDGF-beta) receptor expression levels and signal transduction pathways in NF1 MPNST cell lines and compared them with the expression of PDGF-beta receptors in normal human Schwann cells (nhSC). " 12/01/2009 - "PDGFRA, PDGFRB, and EGFR were immunohistochemically, biochemically, cytogenetically, and mutationally analyzed along with the detection of their cognate ligands in 16 neurofibromatosis type 1 (NF1)-related and 11 sporadic MPNSTs. " Order ALL the reference details at left...
7.	platelet-derived growth factor BB (becaplermin)FDA Link 08/01/2007 - "Platelet-derived growth factor-BB (PDGF-BB) was identified as the most effective MPNST cell invasion-inducing factor. " 02/01/2005 - "Schwann cell lines derived from malignant peripheral nerve sheath tumors respond abnormally to platelet-derived growth factor-BB." 09/01/2011 - "Exogenous prostaglandins alone or in combination with PDGF BB induced greater increases in cAMP levels and proliferation of NF1 MPNST cells compared to nHSC. " 08/01/2007 - "Our results indicated that PDGF-BB enhanced the invasive activity of MPNST cells through PDGFR phosphorylation and that imatinib inhibited such activity. " 02/01/2005 - "However, increased intracellular calcium (Ca2+) levels in response to PDGF-BB were observed only in the NF1 MPNST cell lines; nhSC did not show any increase in intracellular calcium when stimulated with PDGF-BB. " Order ALL the reference details at left...
8.	Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA 08/01/2009 - "Platelet-derived growth factor-BB (PDGF-BB) enhances the invasive activity of malignant peripheral nerve sheath tumor (MPNST) cells through platelet-derived growth factor receptor (PDGFR) phosphorylation, whereas imatinib mesylate inhibited such activity, suggesting that targeting PDGFR-beta may result in the establishment of novel treatment for MPNST. " 02/01/2004 - "To independently verify differential expression, immunohistochemical analyses with antibodies to matrix metalloproteinase 13 (MMP13), platelet-derived growth factor receptor alpha (PDGFRA) and fibronectin (FN1) were performed on 9 dermal and 9 plexiform neurofibromas and 16 MPNST from 19 NF1 patients. " 12/01/2009 - "We investigated the activation of platelet-derived growth factor (PDGF) receptor A (PDGFRA), PDGF receptor B (PDGFRB), epidermal growth factor receptor (EGFR), and their downstream pathways in malignant peripheral nerve sheath tumors (MPNSTs). " Order ALL the reference details at left...
9.	imatinib (Gleevec)FDA Link 08/01/2007 - "The results provide the ground for further assessment of the therapeutic potential of imatinib in suppressing the invasion and growth of MPNST." 03/01/2006 - "In summary, PDGFRA, PDGF and KIT dysregulation as well as growth inhibition of cell culture S462 by imatinib may suggest that MPNST patients benefit from treatment with imatinib." 03/01/2006 - "Mutation and expression of PDGFRA and KIT in malignant peripheral nerve sheath tumors, and its implications for imatinib sensitivity." 08/01/2007 - "Our results indicated that PDGF-BB enhanced the invasive activity of MPNST cells through PDGFR phosphorylation and that imatinib inhibited such activity. " 03/01/2006 - "Imatinib treatment of MPNST cell culture S462 exerted a growth inhibitory effect and prevented PDGF-AA induced PDGFRalpha phosphorylation. " Order ALL the reference details at left...
10.	TransferasesIBA 04/01/2010 - "A novel geranylgeranyl transferase inhibitor in combination with lovastatin inhibits proliferation and induces autophagy in STS-26T MPNST cells." 07/01/2008 - "We have tested the efficacy of two novel farnesyl transferase inhibitors (FTIs), 1 and 2, alone or in combination with lovastatin, on two NF1 malignant peripheral nerve sheath tumor (MPNST) cell lines, NF90-8 and ST88-14. " Order ALL the reference details at left...

Therapies and Procedures

1.	Drug Therapy (Chemotherapy) 01/01/2011 - "this series indicates the role of chemotherapy in treatment of advanced MPNST. " 03/01/2010 - "We present a case of MPNST located intracranially with a good response to chemotherapy." 01/15/2010 - "Currently, the management of MPNSTs includes surgery and radiation; however, conventional chemotherapy is not very effective, underscoring the need for effective biologically-targeted therapies. " 01/01/2009 - "However, because of invasive growth, propensity to metastasise, and limited sensitivity to chemotherapy and radiation, MPNST has a guarded to poor prognosis. " 03/15/2008 - "Radiation and chemotherapy have a role in selected patients with MPNST. " Order ALL the reference details at left...
2.	Radiotherapy 01/01/2012 - "Because of low incidence of MPNST after radiation, it should not be a major decision about giving radiotherapy. " 01/01/2006 - "MPNST of the brachial plexus should be treated with an adequate wide local excision, with adjuvant high-dose radiotherapy pre- or postoperatively. " 04/01/2012 - "Whereas chemotherapy and/or radiotherapy had no promising effect on overall survival rates, complete resection seems to be the most effective treatment for MPNSTs. " 12/15/2012 - "Metronomic therapy may be effective in MPNST where conventional chemotherapy and radiotherapy fails." 04/01/2012 - "Further multicenter studies on the role of chemotherapy and/or radiotherapy for MPNSTs are warranted." Order ALL the reference details at left...
3.	Heterologous Transplantation (Xenotransplantation) 04/01/2011 - "Using human MPNST cell lines and xenograft models we found that a MPNST subset is highly sensitive to HDACis, whereas a fraction is relatively resistant. " 05/01/2008 - "We tested three drugs for single and combinatorial effects on collected MPNST cell lines and in MPNST xenografts. " 02/01/2007 - "Overall, oHSVs showed highly potent antitumor effects against MPNST xenografts, an effect not diminished by EGFR inhibition. " 02/01/2007 - "Testing of therapeutics for MPNST has been hampered by lack of adequate xenograft models. " 09/15/2012 - "Furthermore, an AURKA selective inhibitor, MLN8237, stabilized tumor volume and significantly increased survival of mice with MPNST xenografts. " Order ALL the reference details at left...
4.	Aftercare (After-Treatment) 02/01/2011 - "One child with perineurioma remained clinically stable, and two children improved after treatment of their neoplasm." 07/01/2008 - "Case 1: A 40-year-old man developed a malignant peripheral nerve sheath tumor (MPNST) in the posterior floor of the nasal cavity 10 years after treatment for nasopharyngeal cancer. " 02/01/2005 - "The decreased growth of NF1 MPNST cell lines after treatment with a CAMKII inhibitor is consistent with the view that aberrant activation of the calcium-signaling pathway by PDGF-BB contributes to the formation of MPNST in NF1 patients." Order ALL the reference details at left...
5.	Transplantation (Transplant Recipients) 02/14/2012 - "We tested this in mouse malignant peripheral nerve sheath tumors (MPNSTs) and found that 18% of primary and 49% of passaged MPNST cells from Nf1(+/-); Ink4a/Arf(-/-) mice formed tumors upon transplantation, whereas only 1.8% to 2.6% of MPNST cells from Nf1(+/-); p53(+/-) mice did. " 02/01/1992 - "Sequential morphological studies of rat malignant peripheral nerve sheath tumors induced with ethylnitrosourea were performed by light microscopy, transmission electron microscopy, scanning electron microscopy, immunohistochemistry and nude mice transplantation. " Order ALL the reference details at left...

blog comments powered by Disqus

TREATMENT OPTIONS
for Nerve Sheath Neoplasms,
Ranking and Evidence

*WARNING* This specific disease subtype has a relatively small number of significant evidence outcomes. You may proceed to order anyway, or go back to the search field and enter a more general type of the target illness. Once your report has been ordered, however, we can't refund the purchase.

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. Analytic charts allow you and your physicians to see at a glance the treatment options—including new, promising, off-label and experimental.

Free Updates for 1 Year
All 14 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Evidence References
Sample PDF Report on Psoriasis >>

Price:

$24.95 USD & Delivery via PDF download
updates for 1 year

Research Interface PRO

Rapidly retrieve clinical outcome summaries for all evidence of drug efficacy against any disease in seconds. Click "Charts" to view graphs of relative efficacy of all drugs against any known disease. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time. Save hours of search and analysis time:

Two-clicks from Disease to Drug to Evidence: Drill down to full abstract
Enable Experts: Quickly identify key researchers and their publications
Enable FDA Link Generic: Two-clicks to FDA Products/Patents/Generics
Enable Export: All outcome statements and scores exportable to Excel/TSV for automated meta-analysis
Research Network: Explore drug and disease relationships visually
Enable Mobile Interface: Access from your cellphone, iPhone or PDA

Price:

$490.00 USD access via web interface
1 year subscription

Request Bulk Institution License Details >>